All In Biotech

Drug Trial Radar · NCT07306832

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Apr 2028

Study completion Mar 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML. Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world. Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Pivekimab SunirineDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment DiscontinuationTime frame: Up to Approximately 24 Months
  2. Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)Time frame: Up to Approximately 22 Months
  3. Cmax of FGN849 PayloadTime frame: Up to Approximately 22 Months
  4. Area Under the Concentration-Time Curve (AUC) of Intact ADCTime frame: Up to Approximately 22 Months
  5. AUC of FGN849 payloadTime frame: Up to Approximately 22 Months
  6. Time to Cmax (Tmax) of Intact ADCTime frame: Up to Approximately 22 Months
  7. Tmax of FGN849 PayloadTime frame: Up to Approximately 22 Months

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital /ID# 276015

    Palo Alto, California · Recruiting

  • Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740

    Atlanta, Georgia · Recruiting

  • New York Medical College /ID# 275597

    Valhalla, New York · Recruiting

  • Tristar Centennial Medical Center /ID# 275831

    Nashville, Tennessee · Recruiting

  • Children's Medical Center Dallas /ID# 275930

    Dallas, Texas · Recruiting

  • The Children's Hospital at Westmead /ID# 275672

    Westmead, New South Wales, Australia · Recruiting

  • Perth Children'S Hospital /ID# 275673

    Perth, Western Australia, Australia · Recruiting

  • Hopital Armand Trousseau /ID# 276231

    Paris, France · Recruiting

  • Chu Bordeaux - Hopital Pellegrin /ID# 277645

    Bordeaux, New Aquitaine, France · Recruiting

  • Ospedale Pediatrico Bambino Gesu /ID# 275692

    Rome, Roma, Italy · Recruiting

  • Seoul National University Hospital /ID# 276978

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Samsung Medical Center /ID# 276979

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • National Taiwan University Hospital /ID# 276635

    Taipei, Taiwan · Recruiting

  • Cambridge University Hospital /ID# 277041

    Cambridge, Cambridgeshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.